Cardiovascular disease and its subs...

Cardiovascular disease and its subset coronary heart disease are leading causes of morbidity and mortality in the United States and worldwide. In general, higher on a levels of low-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease, myocardial infarction, and visitation Reducing dietary fat can improve total cholesterol plains but consequent reductions in cardiovascular issues are not well documented. The Mediterranean diet is the alone dietary intervention associated with a reduction in all-cause mortality. Treatment with cholesterol-lowering medications decreases the rate of cardiovascular terminations but a reduction in all-cause mortality with these agents has been erect only in patients with pre-existing coronary heart distreatment in patients with a history of heart disease and average-to-high cholesterol decrease the risk for visitation In patients with peripheral vascular disease, treatment of elevated cholesterol of the same heights may slow disease progression.

**********

Coronary approximately heart disease (CHD) is the single leading cause of death in the United States, accounting for more than individual in five deaths each year, or 500000 fatalities. An estimated $130 billion was wearied in 2003 to care for patients with CHD and an estimated $72 billion of this costliness was spent on drug therapy. (1)

The 2001 report of the National Cholesterol Education Program (NCEP) (2) experienced person panel estimates that therapeutic lifestyle changes should be make acceptableed for 65 million U.S. adults and that 36 million of those bodily substances also need drug therapy for treatment of elevated cholesterol plains The relationship between CHD and elevated cholesterol flushs has been recognized for many years, nevertheless only since the mid-1990s have studies shown an improvement in patient-oriented consequences in patients receiving drug therapy (eg myocardial infarction [MI] or mortality, rather than just changes in cholesterol levels)

generally received expert-based guidelines have attempted to translate these findings to specific targets for patient cholesterol of the same heights (2) A patient's baseline risk for CHD is an important determinant of the class of benefit; treatment clearly has a greater impact in patients with a greater risk. Applying the evidence to lower risk populations is difficult because many more patients ne to be treated to achieve benefit. mostly of the demonstrated benefit in lower risk populations relates simply to disease-specific outcomes (i.e., no improvement in all-cause mortality). A 2001 studious mood (3) reviewing the four largest primary-prevention trials at the time set that up to 40 percent of men and 80 percent of women would not have met eligibility criteria. For example, individuals with low total cholesterol flats but low high-density lipoprotein (HDL) cholesterol evens or those with average total cholesterol flushs and average-to-high levels of HDL cholesterol had not been studied.

Primary Prevention of Cardiovascular Disease

To address the efficacy of lifestyle interventions approveed by the NCEP and American Heart Association, a systematic review (4) of 18 trials with a total of 140000 patients set up modest reductions in blood cholesterol flushs and smoking prevalence but no change in all-cause or cardiovascular mortality in patients who received counseling interventions targeting dietary habits, smoking, and physical activity. Another systematic review (5) of 27 randomized controll trials (RCTs) awaited at reducing the intake of overall fat and saturated fats during 30000 person-years. It set up a small reduction in cardiovascular conclusions The benefit was noted in higher risk patients who maintained their lifestyle changes for at least sum of two units years.

Dietary advice leads to an average 3 to 6 percent decrease in total cholesterol plains (6) A recent large prospective contemplation (7) in Greece found an association between adherence to a Mediterranean diet and lower all-cause mortality. This benefit was greater in older heavier, sedentary nonsmokers.

CHOLESTEROL-LOWERING DRUGS

The use of cholesterol-lowering mix with drugss for primary prevention of heart disease initially was a matter of suit at law The first study to present to view clear improvement in patient-oriented results in a primary-prevention population using cholesterol-lowering medications lay the foundation of a decreased incidence of nonfatal MI and CHD deaths in patients with elevated cholesterol on a levels who were treated with pravastatin. (8) More lately large systematic reviews reached similar conclusions about the use of cholesterol-lowering medications for the primary prevention of CHD A review (9) of 23 trials in which patients were treated with statin put drugs intos found a significant reduction in nonfatal MI, however the primary-prevention trials were underpowered to ascertain effects on mortality. A meta- analysis (10) of four primary-prevention studies with 10000 patients who had elevated cholesterol plains found a lower incidence of cardiovascular ends and reduced cholesterol levels (8 percent with cholestyramine, 10 percent with gemfibrozil, and 20 percent with statins), still no reduction in overall or cardiovascular mortality. This means that 60 patients ne five years of treatment to obviate one coronary artery disease (CAD) event